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Chronic kidney disease from screening, detection, 
and awareness, to prevention
A critical link exists between awareness of risk, the 
presence of disease, and steps taken by the patient and 
clinician to change the natural history of disease. Chronic 
illnesses such as diabetes mellitus, dyslipidaemia, anaemia 
and a multitude of endocrinological and rheumatological 
diseases are relatively silent and rely on the clinical 
laboratory for diagnosis, particularly in their early stages. 
Probably no such illness permits such a large loss of 
organ function before symptoms become present as 
chronic kidney disease (CKD).1 Thus, the considerable 
dependence on the laboratory to establish the diagnosis 
of CKD is an issue for low-income and middle-income 
countries (LMIC), where access to in-vitro diagnostics on 
a screening basis might not be universally available. Even 
in high-income countries where routine laboratory tests 
are performed, CKD seems to lag considerably behind 
diabetes mellitus, hypertension, and cardiovascular 
disease in terms of patient and clinician awareness.2 This 
diﬀ erence is partly due to the two-dimensional nature 
of CKD deﬁ ned as a reduction in estimated glomerular 
ﬁ ltration rate (eGFR) and the presence of markers 
of chronic kidney damage (albuminuria or imaging 
evidence) over 3 months time. Thus, to have the eGFR 
and albumin:creatinine ratio at the same time and clearly 
inform the patient of the potential presence of CKD is 
complex.
With these challenges as the backdrop, Ene-Iordache 
and colleagues3 report on 75 058 individuals screened 
for diabetes mellitus, hypertension, and CKD from 
LMICs. They found 44% of people with hypertension 
and 31% of those with diabetes were unaware of these 
conditions, suggesting public health screening eﬀ orts 
such as those described by the authors have a very high 
yield when there may not be access to primary care and 
routine screening. A total of 14·3% of the population 
was conﬁ rmed to have CKD by eGFR and or proteinuria 
(dipstick or albumin:creatinine ratio). Awareness of CKD 
was less than 10% in all risk groups in line with what has 
been found in the US Kidney Early Evaluation Program 
(KEEP).4 Importantly, less than half of those aware 
reported any treatment or clinical actions taken for CKD. 
Thus, these data seem to present a three-part challenge: 
(1) to screen and detect CKD, (2) to become aware of the 
condition, (3) to understand and act on the knowledge 
that controlling modiﬁ able risk factors like blood pressure 
and glucose can attenuate progression of CKD.
Importantly, the authors demonstrated a sharp 
linkage between risk of CKD and cardiovascular disease 
in young to middle-aged individuals from many regions 
in the world. Thus, the beneﬁ t of CKD screening and 
detection as conveyance of cardiovascular disease risk, 
and the opportunities to modulate this risk, is arguably 
a more optimistic treatment goal than attenuating the 
progression of CKD.5 With the advent of cardiovascular 
disease risk factor reduction there can be a dramatic 
reduction in the binary risks of myocardial infarction, 
stroke, and cardiovascular death.6,7 High-income countries 
are witnessing sharp declines in rates of cardiovascular 
disease events, which are probably attributable to 
population changes in global risk. Additionally, blood 
pressure control is tightly linked to reductions in 
incident heart failure and stroke.8 With half of those with 
hypertension and a third of those with diabetes from 
LMIC in this report taking no medications at all for these 
problems, there appears to be a considerable public health 
opportunity from strengthened community approaches 
Figure: Screening and detection of CKD using estimated GFR (from measured 
serum creatinine) and the spot urine ACR with the identiﬁ cation of 
cardiovascular risk before progression of CKD
GFR=glomerular ﬁ ltration rate. ACR=albumin:creatinine ratio. CKD=chronic 
kidney disease.
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that not only screen and detect disease but also provide 
some basic forms of pharmacological treatment and 
follow-up.9
Results from the present study3 and from over 
a decade of experience with KEEP suggest that 
hypertension, diabetes, smoking, concern for the 
presence of any of these risk factors, or a family history 
of CKD are proven high-yield criteria for individuals 
to undergo screening and measurement of eGFR and 
urine albumin.10 Conﬁ rmation of hypertension or 
diabetes mellitus is a mandatory call to treatment. 
Furthermore, identiﬁ cation of CKD in a middle-
aged individual is a signal for cardiovascular disease 
risk, and additional steps can be taken to reduce the 
rates of myocardial infarction, stroke, heart failure, 
and cardiovascular death (ﬁ gure). It all starts with 
screening and detection of a silent disease, which give 
years of opportunity for discovery and modiﬁ cation of 
its natural history. 
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